What is Fitterfly's Personalised Glycemic Response (PGR) technology?

PGR is an AI-led technology patented by Fitterfly that predicts how specific foods and activities will affect an individual's blood sugar levels up to three hours in advance.

How many people has Fitterfly's PGR technology helped manage diabetes?

Fitterfly's Personalised Glycemic Response technology has already assisted over 40,000 people in better managing their diabetes.

What data does Fitterfly use for its Personalised Glycemic Response predictions?

Fitterfly's PGR technology uses over 10,00,000 CGM readings, along with user data like age, gender, HbA1c, BMI, and activity levels for accurate predictions.

Home / Health / India Patents AI Tech Predicting Food's Sugar Impact

India Patents AI Tech Predicting Food's Sugar Impact

4 Dec, 2025

•

Summary

Fitterfly patented AI tech predicting blood sugar response to food.
The technology uses 10 lakh+ CGM readings and user data for accuracy.
Over 40,000 people have managed diabetes better with this tech.

India Patents AI Tech Predicting Food's Sugar Impact

Fitterfly by PB Health has achieved a significant milestone with a Government of India patent for its innovative Personalised Glycemic Response (PGR) technology. This AI-driven system is designed to predict the impact of food and physical activity on an individual's blood sugar levels, offering insights up to three hours ahead.

The PGR technology has been trained on an extensive dataset of over 10,00,000 Continuous Glucose Monitor (CGM) readings, encompassing numerous meals and user data. It factors in various personal metrics such as age, gender, HbA1c, BMI, and activity levels to provide precise glucose predictions.

This breakthrough has already empowered more than 40,000 individuals in managing their diabetes, demonstrating a significant impact on health markers. Fitterfly's outcome-driven approach, amplified by PGR, is shifting diabetes care from reactive treatment to continuous, proactive management, aiming for long-term stability and potential remission in Type 2 diabetes cases.